

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number  
**WO 2005/051391 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/497**,  
31/517, A01N 43/54, C07D 401/00, 403/00, 413/00,  
417/00, 419/00

(21) International Application Number:  
PCT/US2004/039020

(22) International Filing Date:  
19 November 2004 (19.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/523,336 19 November 2003 (19.11.2003) US  
60/524,492 24 November 2003 (24.11.2003) US

(71) Applicants (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US). **GLAXOSMITHKLINE** [US/US]; Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US).

(71) Applicants and

(72) Inventors: **BOYCE, Rustum, S.** [IN/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608-2917 (US). **SPEAKE, Jason, D.** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US).

(72) Inventor; and




(75) Inventor/Applicant (for US only): **PHILLIPS, James** [US/US]; c/o Curragh Chemistries, Inc., 11000 Cedar Avenue, Suite 285, Cleveland, OH 44106 (US).

(74) Agent: **FRIEDRICHSEN, Bernard, P.**; Foley & Lardner LLP, 150 E. Gilman Street, P.O. Box 1497, Madison, WI 53701-1497 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION



(57) Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB. IA and IB have the following structures where Z has the formula shown below and the rest of the variables are defined herein.

WO 2005/051391 A1



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*